TrialEuropean journal of medical research2024

Efficacy and safety of trimodulin in patients with severe COVID-19: results from a randomised, placebo-controlled, double-blind, multicentre, phase II trial (ESsCOVID).

Alina Agafina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.